Seeking Alpha
26 Feb 2026, 19:04 UTC · 31w ago
Impact · against what's priced in
Ironwood Pharmaceuticals faces significant downward pressure due to a dual blow of eroding core revenue and the loss of a key pipeline asset. The discrepancy between current LINZESS sales trends and aggressive 2026 guidance suggests a looming earnings miss.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
Ironwood Pharmaceuticals declined to exercise its option on CNP-104 for PBC following disappointing data.
More negative than 99% of claims this week
LINZESS U.S. sales decreased 6% to $864.5M in 2025, challenging the company's bullish 2026 guidance of $1.125–$1.175B.
Continue reading
5 related stories
The abandonment of CNP-104 removes a critical growth catalyst, while a 6% drop in 2025 LINZESS sales to $864.5M makes the 2026 guidance of $1.125–$1.175B appear unrealistic.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 95% of claims this week
Ironwood Pharmaceuticals has been downgraded from 'Buy' to 'Sell'.
More negative than 86% of claims this week
Which stocks this story touches
More negative than 89% of ticker scores this week
The company received a downgrade to 'Sell' due to declining LINZESS sales and a lost pipeline catalyst.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Invezz
41m ago
+11.9%
Price is moving against the score
$3.76 vs $3.36 close before publication (Feb 25) · not market-adjusted
IRWD chart →
